Document text
Principal Investigator: Matthew Hall
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2021
Award: $1,912,140
Funding agency: National Center for Advancing Translational Sciences
During this past reporting period, NCATS began development of over a dozen novel assays to screen for potential therapeutic agents against SARS-CoV-2. Optimized assays were then screened against a panel of drug repurposing, clinical candidate and antiviral libraries that have been assembled at NCATS. These results have been made freely available to public with unprecedented speed through the NCATS OpenData Portal and through a number of preprint/journal publications.
These assays include both virus (e.g. Spike protein) and host (e.g. ACE2, TMPRSS) targets, as well as BSL3 live SARS-CoV-2 virus infectivity assays accessed through research contracts. Many assays have been solely developed in-house at NCATS, while a number of others have been designed in collaboration with both intramural and extramural laboratories with subject area expertise.
These collaborations include:
1. Cell-based SARS-CoV-2 ORF3a assay with Dr. Michael Lenardo (NIAID)
2. Recombinant SARS-CoV-2 nsp13 helicase assay with Dr. Robert Brosh (NIA)
3. Cell-based DNA topoisomerase assay with Dr. Yves Pommier (NCI)
4. Recombinant SARS-CoV-2 PLpro assay with Dr. Patricia Legler (Naval Research Laboratory)
5. Combination screening with Dr. Eugene Muratov (University of North Carolina)
One such assay developed in-house was for the biochemical screening of recombinant TMPRSS2 suitable for high throughput applications to enable inhibitor discovery and profiling of FDA-approved therapeutics. The TMPRSS2 assay demonstrated sensitivity to quantify inhibition down to subnanomolar concentrations, and enabled assessment of inhibition of camostat, nafamostat, and gabexate (clinically approved agents in Japan), as well as FOY-251 (a camostat metabolite) and bromhexine hydrochloride, an FDA-approved mucolytic cough suppressant.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><Address><Antiviral Agents><Antiviral Drugs><Antivirals><Area><Assay><Bioassay><Biochemical><Biologic Assays><Biological Assay><Biology><COVID associated pneumonia><COVID induced pneumonia><COVID pneumonia><COVID related pneumonia><COVID-19><COVID-19 assay><COVID-19 associated pneumonia><COVID-19 induced pneumonia><COVID-19 pneumonia><COVID-19 related pneumonia><COVID-19 therapeutics><COVID-19 virus><COVID19><COVID19 assay><COVID19 therapeutics><COVID19 virus><CV-19><CV19><Cell Body><Cells><Clinical><CoV-2><CoV2><Collaborations><Communities><Coughing><DNA Helicases><DNA Topoisomerases><DNA Unwinding Proteins><DNA unwinding enzyme><Data><Development><Disease><Disorder><Drugs><EXTMR><Epitheliasin Gene><Extramural><Extramural Activities><FDA approved><Gabexate><Goals><High Throughput Assay><Infectious Agent><Investigators><Japan><Journals><Knowledge><Laboratories><Laboratory Research><Libraries><Magazine><Medication><Mind><Mucolytic Agents><Mucolytics><NIAID><National Institute of Allergy and Infectious Disease><North Carolina><PRSS10><Pharmaceutic Preparations><Pharmaceutical Preparations><Position><Positioning Attribute><Proteins><Protocol><Protocols documentation><Public Health><Publications><Recombinants><Reporting><Research><Research Activity><Research Contracts><Research Personnel><Research Resources><Research Support><Researchers><Resources><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 assay><SARS-CoV-2 associated pneumonia><SARS-CoV-2 induced pneumonia><SARS-CoV-2 pneumonia><SARS-CoV-2 related pneumonia><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Screening Result><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Site><Societies><Speed><TMPRSS2><TMPRSS2 gene><Testing><Therapeutic><Therapeutic Agents><Therapeutic Intervention><Translational Research><Translational Science><Translations><Universities><Vaccines><Viral Diseases><Virus><Virus Diseases><Work><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral drugs><anti-virals><assay development><atypical pneumonia><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><clinical candidate><clinical efficacy><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 assay><coronavirus disease 2019 associated pneumonia><coronavirus disease 2019 induced pneumonia><coronavirus disease 2019 pneumonia><coronavirus disease 2019 related pneumonia><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease associated pneumonia><coronavirus disease induced pneumonia><coronavirus disease pneumonia><coronavirus disease related pneumonia><design><designing><developmental><drug repurposing><drug/agent><effective therapy><effective treatment><hCoV19><helicase><high throughput screening><infectious organism><inhibitor><inhibitor/antagonist><intervention therapy><nCoV2><novel><pandemic><pandemic disease><pneumonia due to COVID><pneumonia due to COVID-19><pneumonia due to SARS-CoV-2><pneumonia due to coronavirus disease><pneumonia due to coronavirus disease 2019><pneumonia due to severe acute respiratory syndrome coronavirus 2><pneumonia in COVID><pneumonia in COVID-19><pneumonia in SARS-CoV-2><pneumonia in coronavirus disease><pneumonia in coronavirus disease 2019><pneumonia in severe acute respiratory syndrome coronavirus 2><repurposing agent><repurposing medication><screening><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 associated pneumonia><severe acute respiratory syndrome coronavirus 2 induced pneumonia><severe acute respiratory syndrome coronavirus 2 pneumonia><severe acute respiratory syndrome coronavirus 2 related pneumonia><therapeutic agent development><therapeutic development><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><translation research><viral infection><virus infection><virus-induced disease><β CoV><β coronavirus><βCoV>